FDA Approves First Generic Once-Weekly Climara Pro Hormone Patch
On October 20, 2026, the U.S. Food and Drug Administration announced its approval of the first generic equivalent to Climara Pro. Made by Zydus Pharmaceuticals (USA) Inc., the weekly estradiol and levonorgestrel transdermal system delivers 0.045 mg per day of estradiol and 0.015 mg of levonorgestrel. The patch is approved specifically for women with an intact uterus. It combines an estrogen and a progestogen in one product, unlike estrogen-only alternatives. The agency explained that progestogen is included to address endometrial hyperplasia risks linked with using estrogen alone. The FDA stated that the generic matches the brand-name medicine, which carries indications for moderate to severe vasomotor symptoms due to menopause and postmenopausal osteoporosis. Generic options matter to patients because nine out of 10 prescriptions filled in the United States are generic drugs. The agency noted that introducing generic competition helps make care more affordable and expands access to medications for more people.
What was announced
The U.S. Food and Drug Administration approved an application from Zydus Pharmaceuticals (USA) Inc. for a generic estradiol and levonorgestrel transdermal system. The patch delivers 0.045 mg per day of estradiol and 0.015 mg of levonorgestrel, applied once per week.
This patch is therapeutically equivalent to Bayer's brand-name drug Climara Pro. It is approved for women with an intact uterus. The listed indications cover moderate to severe vasomotor symptoms due to menopause, alongside postmenopausal osteoporosis. Unlike estrogen-only patches, this formulation adds a progestogen to reduce the risk of endometrial hyperplasia, an abnormal thickening of the uterine lining associated with taking estrogen alone.
What it means
A transdermal system is an adhesive patch that delivers medication through the skin into the bloodstream. Because this patch requires application only once each week, it provides an alternative to taking pills every day. Michael Davis, Director of the FDA's Center for Drug Evaluation and Research, said this schedule may help patients stay on track with their regimens.
Safety warnings accompany the approval. The patch is contraindicated for patients with undiagnosed abnormal genital bleeding, breast cancer or a history of breast cancer, estrogen-dependent neoplasia, liver disease, certain blood-clotting disorders, or a history of deep vein thrombosis and pulmonary embolism. Reported adverse reactions occurring in at least 5% of patients include application site irritation, vaginal bleeding, breast pain, headache, depression, and back pain.
According to the agency, generic medications make up nine out of 10 prescriptions filled in the United States. Adding a generic alternative creates marketplace competition that may help lower medication expenses.
What the announcement does not tell us
Retail pricing and insurance coverage details are missing from the release. The agency did not state what patients will pay at the pharmacy counter.
Commercial rollout timing remains unmentioned as well. Readers are directed to contact Zydus Pharmaceuticals directly to learn when the medicine will become available.
How this was written
This analysis was written with AI from the official announcement below, using only facts that announcement states. The quoted wording is FDA Press Announcements’s own. Always check the original before acting on anything here.
Today, the U.S. Food and Drug Administration approved the first generic of Climara Pro (estradiol and levonorgestrel transdermal system, 0.045 mg per day/0.015 mg), a transdermal hormone therapy patch for women with an intact uterus applied once a week.
Opens www.fda.gov
More from FDA Press Announcements
This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program: especially if you are pregnant, nursing, taking medication, or managing a health condition.